Omicron News and Research

RSS

SARS-CoV-2 Omicron associated with fewer lower and more upper respiratory tract symptoms

Researchers assess the impact of the SARS-CoV-2 Omicron variant of concern on symptoms of SARS-CoV-2 infection.

23 Jan 2022

Paxlovid provides a glimpse into the future against SARS-CoV-2

A recent study reveals that nirmatrelvir is potent and effective against the SARS-CoV-2 Omicron variant.

23 Jan 2022

Impact of booster vaccines against SARS-CoV-2 Omicron variant

Researchers explore the dynamics of COVID-19 vaccine-induced protection against SARS-CoV-2 variants of concern.

23 Jan 2022

MU researchers identify highly prevalent mutations specific to Omicron variant

While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant's high rate of infection.

22 Jan 2022

Omicron found to have higher environmental stability among SARS-CoV-2 variants

A new study compared the SARS-CoV-2 Wuhan strain and all the variants of concern (VOCs) - Alpha, Beta, Delta, and Omicron variants for their survivability and infectivity.

21 Jan 2022

Researchers design neural network to predict severity of COVID-19 variants

In a new study, researchers predict the risk of infection with severe coronavirus disease 2019 from the sequence of the spike protein.

21 Jan 2022

Vaccines alone are ineffective against the widely circulating Omicron variant

Millions of people around the world have received two shots of Sinovac, a Chinese-manufactured inactive vaccine that is used in 48 countries to help reduce transmission rates of COVID-19.

21 Jan 2022

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

In a new study, researchers assessed the efficacy of the FDA-approved therapeutic mAbs, as well as to small-molecule antiviral agents against the SARS-CoV-2 Omicron variant in Syrian hamsters.

21 Jan 2022

Study supports that Omicron variant has shifted to better usage of Cathepsin B/L entry pathway

A new study analyzed new data on the Omicron variant and indicated the altered cell entry pathways compared to other variants.

21 Jan 2022

Exploring the likelihood of SARS-CoV-2 becoming an endemic disease

Several deadly pandemics have emerged in human history that have either disappeared or turned into epidemics. Researchers explored the likelihood that SARS-CoV-2 would also eventually become an endemic disease.

21 Jan 2022

New COVID-19 vaccine promises vaccine equity because it has no patents

Corbevax, a new vaccine against COVID-19, may have better success as a candidate for vaccine equity because it carries no patents, relies on long-established recombinant technology for manufacture and has the support of the US and Indian governments, its makers and health experts say.

21 Jan 2022

Study suggests SARS-CoV-2 Omicron variant spike mediated immune escape and tropism shift

A new study showed that the SARS-CoV-2 Omicron spike binds to its receptor with enhanced affinity and yet evades vaccine-elicited neutralizing antibodies and that a booster mRNA vaccine broadened the neutralization of Omicron.

21 Jan 2022

Patient, beware: Some states still pushing ineffective covid antibody treatments

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes covid-19.

21 Jan 2022

Nano-bubbles containing ACE2 protein can block infection from broad strains of SARS-CoV-2

Scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients and discovered these nano-sized particles can block infection from broad strains of SARS-CoV-2 virus in preclinical studies.

21 Jan 2022

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

A recent study, currently available on bioRxiv* preprint server, shows that a novel protease inhibitor known as nirmatrelvir has potent activity against Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other variants evaluated in this paper – which supports its potential role in reducing the disease burden from coronavirus disease 2019 (COVID-19).

21 Jan 2022

Omicron News and Research

SARS-CoV-2 Omicron associated with fewer lower and more upper respiratory tract symptoms

Paxlovid provides a glimpse into the future against SARS-CoV-2

Impact of booster vaccines against SARS-CoV-2 Omicron variant

MU researchers identify highly prevalent mutations specific to Omicron variant

Omicron found to have higher environmental stability among SARS-CoV-2 variants

Researchers design neural network to predict severity of COVID-19 variants

Vaccines alone are ineffective against the widely circulating Omicron variant

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

Study supports that Omicron variant has shifted to better usage of Cathepsin B/L entry pathway

Exploring the likelihood of SARS-CoV-2 becoming an endemic disease

New COVID-19 vaccine promises vaccine equity because it has no patents

Study suggests SARS-CoV-2 Omicron variant spike mediated immune escape and tropism shift

Patient, beware: Some states still pushing ineffective covid antibody treatments

Nano-bubbles containing ACE2 protein can block infection from broad strains of SARS-CoV-2

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

Indian study suggests significant decrease in protection from vaccine or natural immunity against Omicron variant

Research shows benefits of hybrid immunity to SARS-CoV-2

SARS-CoV-2 breakthrough infections elicit potent neutralizing antibody responses

Scientists explore the possibility of Omicron ending the COVID-19 pandemic

RASCL: new analytic pipeline for investigating selective forces acting on viral genes in SARS-CoV-2 sequences

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News